1-5 of 5
Apurv Agrawal
Close
Sort by
Journal Articles

High Rate of Disease Progression in Patients with Low-Risk Myelofibrosis (MF) Enrolled in the Prospective, Real-World MOST Study

Michael R. Grunwald, Aaron T. Gerds, Apurv Agrawal, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, John Mascarenhas
Journal: Blood
Blood (2023) 142 (Supplement 1): 3803.
https://doi.org/10.1182/blood-2023-174523
Published: 2023
Journal Articles

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Maro Ohanian, Tara L. Lin, Ellen Ritchie, Michael Craig, Apurv Agrawal, Kathleen G. Halka, Naveen Pemmaraju, Gautam Borthakur, Miranda Lim, Sherry A. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1281.
https://doi.org/10.1182/blood-2021-152750
Published: 2021
Journal Articles

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Abdulraheem Yacoub, MD, Roger M. Lyons, MD, Srdan Verstovsek, MD PhD, Ryan Shao, MD, David Tin Chu, MD, Apurv Agrawal, MD, Smitha Sivaraman, PhD, Philomena Colucci, DO, MS, Peter Yao, John Mascarenhas, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4306.
https://doi.org/10.1182/blood-2018-99-112183
Published: 2018
Journal Articles

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Maro N. Ohanian, DO, Tara L Lin, MD, Ellen K. Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Vinit Karur, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Sarah Aminov, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Natalie Sacarakis, Stacy Minor, Ana Tari Ashizawa, PhD, William Hahne, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1387.
https://doi.org/10.1182/blood-2018-99-113693
Published: 2018
Journal Articles

A Phase 2 Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to 5-Azacitadine: A Preliminary Analysis of Phase 2a

Ellen K. Ritchie, MD, Apurv Agrawal, MD, Kashyap B Patel, MD, Seth Rosen, MD, Amy Law, MD BA, Jeffrey M Skolnik, MD, Ashkan Lashkari, MD
Journal: Blood
Blood (2015) 126 (23): 2904.
https://doi.org/10.1182/blood.V126.23.2904.2904
Published: 2015